Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

Matthew James Walton; Mark Stephen Corbett; Martin Wanyoike Njoroge; Lucy Beresford; Melissa Harden; Robert Hodgson; Sofia Dias

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

Matthew James Walton, Mark Stephen Corbett, Martin Wanyoike Njoroge, Lucy Beresford, Melissa Harden, Robert Hodgson, Sofia Dias

Research output: Book/Report › Commissioned report

Original language	English
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 9 Feb 2023

Access to Document

https://www.nice.org.uk/guidance/ta909/documents/committee-papers

Cite this

@book{5a8cabfd98c8434e8fb7759ea8ef948c,

title = "Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer",

author = "Walton, {Matthew James} and Corbett, {Mark Stephen} and Njoroge, {Martin Wanyoike} and Lucy Beresford and Melissa Harden and Robert Hodgson and Sofia Dias",

year = "2023",

month = feb,

day = "9",

language = "English",

}

TY - BOOK

T1 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

AU - Walton, Matthew James

AU - Corbett, Mark Stephen

AU - Njoroge, Martin Wanyoike

AU - Beresford, Lucy

AU - Harden, Melissa

AU - Hodgson, Robert

AU - Dias, Sofia

PY - 2023/2/9

Y1 - 2023/2/9

M3 - Commissioned report

BT - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

ER -